Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 483

Sort by

Sort Order Select

Journal Articles

On the road to optimized BTK inhibition in CLL

Lukáš Smolej

Blood (2021) 137 (24): 3313–3314.

https://doi.org/10.1182/blood.2021011462

Published: 2021

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3836.

https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Caspar Da Cunha-Bang, MD PhD, Rudy Agius, Arnon P. Kater, Mark-David Levin, MD PhD, Anders Österborg, MD PhD, Mattias Mattsson, MD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4304.

https://doi.org/10.1182/blood-2019-121907

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 3035.

https://doi.org/10.1182/blood-2019-123419

Published: 2019

Journal Articles

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Herve Ghesquieres, MD PhD, Olivier Casasnovas, MD, Emmanuelle Nicolas-Virelizier, MD, Damaj Gandhi Laurent, MD PhD, Vincent Delwail, MD, Mohamed Touati, MD, Katell Le Du, MD, Franck Morschhauser, MD PhD, Christophe Bonnet, MD, Agathe Waultier-Rascalou, MD, Frederique Orsini-Piocelle, MD, Marc André, Myriam Ben Boutieb, Fabienne Morand, Diane Damotte, MD PhD, Alexandra Traverse-Glehen, MD PhD, Philippe Quittet, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 2832.

https://doi.org/10.1182/blood-2019-129016

Published: 2019

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Alison R. Sehgal, MD, John Godwin, John Pribble, Lei Wang, PhD, Jerill Thorpe, BSc, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 2882.

https://doi.org/10.1182/blood-2019-127658

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Divaya Bhutani, MD, Siyang Leng, MD, Samuel Pan, Amer Assal, MD, Alexander Wei, Julia Gould, BA, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3196.

https://doi.org/10.1182/blood-2019-130207

Published: 2019

Journal Articles

Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation

Maria Stamouli, Ioannis Tsonis, MD, Konstantinos Gkirkas, Christina Economopoulou, Thomas Thomopoulos, MD, Anna Paisiou, MD, Nikolaos Siafakas, Spyridon Pournaras, Anastasia Antoniadou, Aggeliki Karagiannidi, Joseph Meletiadis, Dimitra Kavatha, George Vassilopoulos, MD PhD, Stavros Gigantes, MD, Ioannis Baltadakis, MD, Evgenios Goussetis, Dimitrios Karakasis, MD, Panagiotis Tsirigotis

Blood (2019) 134 (Supplement_1): 4498.

https://doi.org/10.1182/blood-2019-128362

Published: 2019

Journal Articles

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Jennifer R Brown, MD PhD, Barbara F. Eichhorst, MD, Paolo Ghia, MD PhD, Arnon P. Kater, MD PhD, Jianyong Li, MD, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, PhD, John F. Seymour, MBBS, PhD FRACP

Blood (2019) 134 (Supplement_1): 4318.

https://doi.org/10.1182/blood-2019-123057

Published: 2019

Journal Articles

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Trisha Kissoon, MD MBA

Blood (2019) 134 (Supplement_1): 5062.

https://doi.org/10.1182/blood-2019-129511

Published: 2019

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

Journal Articles

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Pieter Sonneveld, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Thierry Facon, MD, Cyrille Hulin, MD, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, MD, Sarah Cote, Philippe Moreau, MD

Blood (2019) 134 (Supplement_1): 4739.

https://doi.org/10.1182/blood-2019-122775

Published: 2019

Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 4740.

https://doi.org/10.1182/blood-2019-123491

Published: 2019

NARROW

On the road to optimized BTK inhibition in CLL

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only